Clinical outcome after discontinuing anticoagulant therapy (patients not receiving anticoagulation are also included)
| Metastases | No metastases | Hazard ratio (95% CI) or p-value | |||
| n | Events per 100 patient-years (95% CI) | n | Events per 100 patient-years (95% CI) | ||
| Patients n | 136 | 93 | |||
| Duration of therapy days mean±sd | 242±310 | 303±395 | |||
| Duration days median (interquartile range) | 134 (47–302) | 155 (45–463) | |||
| Duration n (%) | |||||
| <3 months | 49 (36) | 37 (40) | 0.581 | ||
| 3–6 months | 32 (24) | 12 (13) | 0.060 | ||
| >6 months | 55 (40) | 44 (47) | 0.342 | ||
| Symptomatic pulmonary embolism | 12 | 13.3 (7.21–22.6) | 2 | 2.60 (0.44–8.57) | 5.13 (1.30–33.8) |
| Recurrent deep vein thrombosis | 9 | 9.97 (4.86–18.3) | 3 | 3.89 (0.99–10.6) | 2.56 (0.72–11.7) |
| Major bleeding | 3 | 3.34 (0.85–9.10) | 2 | 2.60 (0.44–8.59) | 1.29 (0.19–10.8) |
| Sites of major bleeding | |||||
| Gastrointestinal | 3 | 3.34 (0.85–9.10) | 1 | 1.30 (0.07–6.41) | 2.57 (0.27–67.7) |
| Retroperitoneal | 0 | 1 | 1.30 (0.06–6.40) | ||
| Non-major bleeding | 2 | 2.22 (0.37–7.35) | 2 | 2.60 (0.44–8.58) | 0.86 (0.09–8.22) |
| Death | 68 | 75.3 (58.9–94.9) | 16 | 20.8 (12.3–33.0) | 3.63 (2.14–6.44) |
| Causes of death | |||||
| Disseminated malignancy | 53 | 58.7 (44.4–76.2) | 9 | 11.7 (5.70–21.4) | 5.03 (2.57–10.8) |
| Infection | 2 | 2.22 (0.37–7.32) | 1 | 1.30 (0.06–6.40) | 1.71 (0.13–50.3) |
| Respiratory insufficiency | 3 | 3.32 (0.85–9.04) | 0 | ||
| Ischaemic stroke | 1 | 1.11 (0.06–5.46) | 1 | 1.30 (0.06–6.40) | 0.85 (0.02–33.3) |
| Liver insufficiency | 1 | 1.11 (0.06–5.46) | 1 | 1.30 (0.06–6.40) | 0.85 (0.02–33.3) |
| Pulmonary embolism | 1 | 1.11 (0.06–5.46) | 0 | ||
| Bleeding | 0 | 1 | 1.30 (0.06–6.40) | ||
| Multi-organ failure | 0 | 1 | 1.30 (0.06–6.40) | ||
| Unknown | 3 | 3.32 (0.85–9.04) | 2 | 2.60 (0.44–8.57) | 1.28 (0.19–10.8) |